Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT01905943 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01905943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01905943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
November 4, 2013
Completion date
October 8, 2018
Enrollment
979 (actual)
Sites
174

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia